CITF Research Roundup | Issue 41 | November 17, 2021

CITF Events


Please take note! The 3rd event in our CITF/CanCOVID Seminar Series: Research Results & Implications, looking at the impact of COVID-19 disease & vaccination on pregnancy and newborns, will take place:

Monday, December 20, 2021 11:30 am – 1:00 pm EST
CITF-funded experts Dr. Deshayne Fell of the University of Ottawa and the Children’s Hospital of Eastern Ontario Research Institute; Dr. Deborah Money of the University of British Columbia and BC Women’s Hospital; and Dr. Deborah O’Connor of the University of Toronto will present their latest findings, which have been used to help inform decision making. Their presentations will be followed by a lively question and answer session.

Registration link to come!

Watch the seminar on protecting Canada’s long-term care residents from COVID-19

Now available, video of the second CITF/CanCOVID seminar series on immunity among residents and staff in long-term care homes, as well as older adults living in the community.

Watch the seminar

CITF-Funded Research Results

COVID infections in children and teens continue to rise, study finds

CITF-funded researcher Dr. Kate Zinszer, from the Université de Montréal, and her EnCORE study team have released additional preliminary, non-peer reviewed results indicating a increase in the number of Montreal youth aged 2 to 17 with antibodies due to a SARS-CoV-2 infection in recent months. They found that 9.7% of participants had antibodies to SARS-CoV-2 between May and August 2021, whereas 5.8% had antibodies between October 2020 and March 2021. The parents of 86% of the participants reported their children over 12 were vaccinated or that they intended to have their child vaccinated against COVID-19 when vaccines are available.

Read More

One in five vaccinated long-term care residents at risk of COVID-19 because of low antibody levels, supporting need for booster shots

Findings from a CITF-funded study led by Drs. Andrew Costa and Dawn Bowdish at McMaster University helped inform the federal government’s decision to recommend a third dose of COVID-19 vaccine for long-term care residents. More than 97% of residents produced an antibody response following two doses of vaccination that was likely to provide protection against the virus in the month after the jab. However, three to five months following the second dose, researchers found a drop in antibody levels in about 20% of residents, to the point where their antibody levels may not be high enough to provide effective protection. Their research is published in The Journal of the American Medical Directors Association.

Read More

Incarcerated individuals face an increased risk of acquiring COVID-19

Congregate settings (such as prisons, long-term care homes) allow for the rapid spread of COVID-19. As part of her CITF-funded study in three provincial prisons in Quebec, Dr. Nadine Kronfli from the Research Institute of the McGill University Health Centre found that of the 1,100 incarcerated men sampled, 22% were seropositive for a previous SARS-CoV-2 infection. These findings were recently released in a Lancet preprint, therefore not yet peer reviewed.

Read More

A test to help diagnose vaccine-induced clotting disorders

CITF-funded researcher Dr. Ishac Nazy and researchers affiliated with the McMaster Platelet Immunology Laboratory have found a novel method for diagnosing very rare cases of blood clotting disorders following immunization with mRNA vaccines. This test could significantly improve the early detection of vaccine-induced thrombocytopenia (VIT). The findings are published in Blood Advances.

Read More


Know policymakers or researchers who may be interested in our latest research results? Please share this email and encourage them to subscribe!

Sign Up

Have a publication we should review or know about? Please share with us at

Missed an issue of Research Roundup? View back issues.

The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.

Copyright © 2021 COVID-19 Immunity Task Force | Groupe de travail sur l’immunité face à la COVID-19, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp